10X GENOMICS INC-CLASS A (TXG) Fundamental Analysis & Valuation

NASDAQ:TXG • US88025U1097

Current stock price

17.35 USD
-0.74 (-4.09%)
At close:
17.19 USD
-0.16 (-0.92%)
After Hours:

This TXG fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. TXG Profitability Analysis

1.1 Basic Checks

  • TXG had negative earnings in the past year.
  • TXG had a positive operating cash flow in the past year.
  • In the past 5 years TXG always reported negative net income.
  • In multiple years TXG reported negative operating cash flow during the last 5 years.
TXG Yearly Net Income VS EBIT VS OCF VS FCFTXG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200M -400M

1.2 Ratios

  • TXG has a Return On Assets of -4.18%. This is comparable to the rest of the industry: TXG outperforms 54.39% of its industry peers.
  • Looking at the Return On Equity, with a value of -5.47%, TXG is in line with its industry, outperforming 56.14% of the companies in the same industry.
Industry RankSector Rank
ROA -4.18%
ROE -5.47%
ROIC N/A
ROA(3y)-16.83%
ROA(5y)-14.47%
ROE(3y)-21.87%
ROE(5y)-18.67%
ROIC(3y)N/A
ROIC(5y)N/A
TXG Yearly ROA, ROE, ROICTXG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400

1.3 Margins

  • TXG has a Gross Margin of 69.13%. This is amongst the best in the industry. TXG outperforms 91.23% of its industry peers.
  • In the last couple of years the Gross Margin of TXG has declined.
  • TXG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.13%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.4%
GM growth 5Y-2.99%
TXG Yearly Profit, Operating, Gross MarginsTXG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. TXG Health Analysis

2.1 Basic Checks

  • TXG does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • TXG has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for TXG has been increased compared to 5 years ago.
  • TXG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TXG Yearly Shares OutstandingTXG Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
TXG Yearly Total Debt VS Total AssetsTXG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • TXG has an Altman-Z score of 4.31. This indicates that TXG is financially healthy and has little risk of bankruptcy at the moment.
  • TXG has a Altman-Z score of 4.31. This is amongst the best in the industry. TXG outperforms 85.96% of its industry peers.
  • There is no outstanding debt for TXG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 4.31
ROIC/WACCN/A
WACC10.82%
TXG Yearly LT Debt VS Equity VS FCFTXG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M 800M

2.3 Liquidity

  • A Current Ratio of 4.46 indicates that TXG has no problem at all paying its short term obligations.
  • The Current ratio of TXG (4.46) is better than 71.93% of its industry peers.
  • TXG has a Quick Ratio of 4.09. This indicates that TXG is financially healthy and has no problem in meeting its short term obligations.
  • TXG has a better Quick ratio (4.09) than 73.68% of its industry peers.
Industry RankSector Rank
Current Ratio 4.46
Quick Ratio 4.09
TXG Yearly Current Assets VS Current LiabilitesTXG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. TXG Growth Analysis

3.1 Past

  • TXG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 71.71%, which is quite impressive.
  • TXG shows a small growth in Revenue. In the last year, the Revenue has grown by 5.25%.
  • The Revenue has been growing by 16.56% on average over the past years. This is quite good.
EPS 1Y (TTM)71.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.5%
Revenue 1Y (TTM)5.25%
Revenue growth 3Y7.57%
Revenue growth 5Y16.56%
Sales Q2Q%0.61%

3.2 Future

  • Based on estimates for the next years, TXG will show a very strong growth in Earnings Per Share. The EPS will grow by 26.18% on average per year.
  • TXG is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.75% yearly.
EPS Next Y-126.62%
EPS Next 2Y-33.01%
EPS Next 3Y-5.65%
EPS Next 5Y26.18%
Revenue Next Year-3.55%
Revenue Next 2Y1.71%
Revenue Next 3Y3.77%
Revenue Next 5Y5.75%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
TXG Yearly Revenue VS EstimatesTXG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
TXG Yearly EPS VS EstimatesTXG Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -1 -2 -3 -4 -5

More info and screens

Find the best growth stocksShow best growing peers

2

4. TXG Valuation Analysis

4.1 Price/Earnings Ratio

  • TXG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TXG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TXG Price Earnings VS Forward Price EarningsTXG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

  • 87.72% of the companies in the same industry are more expensive than TXG, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 17.03
EV/EBITDA N/A
TXG Per share dataTXG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • A cheap valuation may be justified as TXG's earnings are expected to decrease with -5.65% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-33.01%
EPS Next 3Y-5.65%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TXG Dividend Analysis

5.1 Amount

  • No dividends for TXG!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TXG Fundamentals: All Metrics, Ratios and Statistics

10X GENOMICS INC-CLASS A

NASDAQ:TXG (3/18/2026, 8:00:01 PM)

After market: 17.19 -0.16 (-0.92%)

17.35

-0.74 (-4.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-12
Earnings (Next)05-06
Inst Owners107%
Inst Owner Change0.76%
Ins Owners1.61%
Ins Owner Change9.67%
Market Cap2.22B
Revenue(TTM)642.82M
Net Income(TTM)-43.54M
Analysts70.91
Price Target20.33 (17.18%)
Short Float %14.19%
Short Ratio6.25
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.91%
Min EPS beat(2)24.4%
Max EPS beat(2)39.41%
EPS beat(4)4
Avg EPS beat(4)65.69%
Min EPS beat(4)24.36%
Max EPS beat(4)174.61%
EPS beat(8)7
Avg EPS beat(8)34.54%
EPS beat(12)7
Avg EPS beat(12)12.19%
EPS beat(16)9
Avg EPS beat(16)9.62%
Revenue beat(2)2
Avg Revenue beat(2)3.37%
Min Revenue beat(2)3.21%
Max Revenue beat(2)3.54%
Revenue beat(4)4
Avg Revenue beat(4)11.32%
Min Revenue beat(4)3.21%
Max Revenue beat(4)22.78%
Revenue beat(8)6
Avg Revenue beat(8)5.2%
Revenue beat(12)9
Avg Revenue beat(12)4.07%
Revenue beat(16)12
Avg Revenue beat(16)3.14%
PT rev (1m)10.28%
PT rev (3m)20.54%
EPS NQ rev (1m)-3.04%
EPS NQ rev (3m)-3.21%
EPS NY rev (1m)-1.63%
EPS NY rev (3m)-1.1%
Revenue NQ rev (1m)2.13%
Revenue NQ rev (3m)2.61%
Revenue NY rev (1m)0.33%
Revenue NY rev (3m)0.57%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.45
P/FCF 17.03
P/OCF 16.29
P/B 2.78
P/tB 3.04
EV/EBITDA N/A
EPS(TTM)-0.43
EYN/A
EPS(NY)-0.97
Fwd EYN/A
FCF(TTM)1.02
FCFY5.87%
OCF(TTM)1.06
OCFY6.14%
SpS5.03
BVpS6.23
TBVpS5.71
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -4.18%
ROE -5.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.13%
FCFM 20.24%
ROA(3y)-16.83%
ROA(5y)-14.47%
ROE(3y)-21.87%
ROE(5y)-18.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.4%
GM growth 5Y-2.99%
F-Score5
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 16.4%
Cap/Sales 0.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.46
Quick Ratio 4.09
Altman-Z 4.31
F-Score5
WACC10.82%
ROIC/WACCN/A
Cap/Depr(3y)64.39%
Cap/Depr(5y)238.34%
Cap/Sales(3y)3.71%
Cap/Sales(5y)11.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.5%
EPS Next Y-126.62%
EPS Next 2Y-33.01%
EPS Next 3Y-5.65%
EPS Next 5Y26.18%
Revenue 1Y (TTM)5.25%
Revenue growth 3Y7.57%
Revenue growth 5Y16.56%
Sales Q2Q%0.61%
Revenue Next Year-3.55%
Revenue Next 2Y1.71%
Revenue Next 3Y3.77%
Revenue Next 5Y5.75%
EBIT growth 1Y48.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-237.31%
EBIT Next 3Y-11.54%
EBIT Next 5Y6.3%
FCF growth 1Y2033.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1941.57%
OCF growth 3YN/A
OCF growth 5YN/A

10X GENOMICS INC-CLASS A / TXG Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for 10X GENOMICS INC-CLASS A?

ChartMill assigns a fundamental rating of 4 / 10 to TXG.


What is the valuation status of 10X GENOMICS INC-CLASS A (TXG) stock?

ChartMill assigns a valuation rating of 2 / 10 to 10X GENOMICS INC-CLASS A (TXG). This can be considered as Overvalued.


Can you provide the profitability details for 10X GENOMICS INC-CLASS A?

10X GENOMICS INC-CLASS A (TXG) has a profitability rating of 2 / 10.


Can you provide the financial health for TXG stock?

The financial health rating of 10X GENOMICS INC-CLASS A (TXG) is 8 / 10.